<DOC>
	<DOCNO>NCT02289833</DOCNO>
	<brief_summary>This Phase 2 , multicenter , single-arm , two cohort study design evaluate efficacy safety trastuzumab emtansine single-agent patient HER2-positive locally advanced metastatic non-small cell lung cancer ( NSCLC ) . Patients enrol two separate cohort , depend HER2 status : HER2 immunohistochemistry ( IHC ) 2+ HER2 IHC 3+ . Patients cohort treat intravenous dose 3.6 mg/kg trastuzumab emtansine Day 1 21-day cycle . Patients remain study disease progression ( assessed investigator ) , unmanageable toxicity , study termination Sponsor .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine Patients With HER2 IHC-Positive , Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Age &gt; /= 18 year Histologically cytologically document diagnosis Stage IIIB amenable radical treatment Stage IV NSCLC ; pathological characterization must determine nonsquamous squamous histological subtype well adenocarcinoma subtype classification . HER2 status IHC 2+ 3+ determine Sponsordesignated central laboratory Prior treatment least one regimen platinumbased ( cisplatin carboplatin ) chemotherapy locally advance metastatic setting/recurrent NSCLC document disease progression investigator assessment Patients know ALK fusion oncogene ( must document patient 's chart ) must also experience disease progression intolerance firstline ALK Tyrosine Kinase Inhibitor ( TKI ) approve treatment ALK fusion oncogene NSCLC ( e.g. , crizotinib ) . Disease progression intolerance must document Patients know mutation EGFR gene ( must document patient 's chart ) must also experience disease progression intolerance EGFR TKI approve treatment EGFRmutant NSCLC ( e.g. , gefitinib , erlotinib , afatinib ) . Disease progression intolerance must document Measurable disease determine per Response Evaluation Criteria Solid Tumors ( RECIST ) , version 1.1 Life expectancy &gt; /= 12 week Adequate organ function Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Left ventricular ejection fraction ( LVEF ) &gt; /= 50 % either echocardiogram ( ECHO ) multiplegated acquisition ( MUGA ) Use highly effective contraception CancerRelated Criteria Any approve anticancer therapy &lt; /= 21 day ( include chemotherapy hormonal therapy ) first study treatment ; follow exception allow : ( 1 ) TKIs approve treatment NSCLC must discontinue &gt; 7 day prior first study treatment Cycle 1 , Day 1 ( The baseline compute tomography scan must complete discontinuation TKIs ) ; ( 2 ) Hormonereplacement therapy oral contraceptive ; ( 3 ) Antiemetics , GCSF , prophylactic antibiotic allow accord local standard Investigational therapy participation another clinical study therapeutic intent &lt; /= 21 day first study treatment Previous irradiation permit &gt; /= 14 day since last fraction radiotherapy elapse first study treatment Day 1 Cycle 1 long sufficient number target lesion remain allow measurable disease per RECIST v1.1 . Patients untreated brain metastasis symptomatic ; patient treat brain metastasis must discontinue corticosteroid therapy neurological symptom History intolerance ( include Grade 3 4 infusion reaction ) hypersensitivity trastuzumab murine protein excipient product History exposure follow cumulative dos anthracyclines : Doxorubicin liposomal doxorubicin &gt; 500 mg/m2 ; Epirubicin &gt; 900 mg/m2 ; Mitoxantrone &gt; 120 mg/m2 . If another anthracycline , one anthracycline , use , cumulative dose must exceed equivalent 500 mg/m2 doxorubicin . Current peripheral neuropathy Grade &gt; /= 3 per National Cancer Institute Common Toxicity Criteria Adverse Events ( NCI CTCAE ) v. 4.0 History malignancy within last 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , cancer similar outcome mention . Cardiopulmonary Function Criteria Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure Severe dyspnea rest due complication advance malignancy require current continuous oxygen therapy Clinical history active hemoptysis Evidence active pneumonitis screen Current unstable ventricular arrhythmia require treatment History symptomatic congestive heart failure ( CHF ; New York Heart Association [ NYHA ] Classes IIIV ) History myocardial infarction unstable angina within 6 month enrollment History decrease LVEF &lt; 50 % General Criteria Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , metabolic disease ) Major surgical procedure significant traumatic injury within 28 day enrollment anticipation need major surgery course study treatment Current pregnancy lactation Current know active infection HIV , hepatitis B , hepatitis C virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>